

OFFICE OF NAVAL RESEARCH
CONTRACT N00014-88-C-0118

TECHNICAL REPORT 94-03

IMMUNE RESPONSES TO MHC HOMOZYGOUS LYMPHOID CELLS IN MURINE F1
HYBRID RECIPIENTS: IMPLICATIONS FOR TRANSFUSION ASSOCIATED
GRAFT-VERSUS HOST DISEASE

BY

L.D. FAST, C.R. VALERI, AND J.P. CROWLEY

NAVAL BLOOD RESEARCH LABORATORY
BOSTON UNIVERSITY SCHOOL OF MEDICINE
615 ALBANY STREET
BOSTON, MA 02118

6 JUNE 1994

Reproduction in whole or in part is permitted for any purpose of
the United States Government.

Distribution of this report is unlimited.

DTIC QUALITY INSPECTED 1

19990225166

ABSTRACT

Graft-versus-host disease(GVHD) is currently encountered following bone marrow transplantation and transfusion. GVHD associated with transfusion(TA-GVHD) in apparently immunocompetent recipients has been recently reported with increasing frequency. A consistent finding in many of these cases is that the recipient received blood from a donor homozygous for one of the the recipient's HLA haplotypes. However the observed frequency of TA-GVHD is much lower than the estimated probability of this donor/recipient combination. The potential role of recipient immune responses in controlling TA-GVHD was investigated using an analogous murine model where GVHD is induced by the injection of parental lymphoid cells into unirradiated F₁ hybrid recipients. The effect of various immune manipulations of the recipient on GVHD induction was assessed by determining the number of donor lymphoid cells required to induce GVHD responses. While depletion of recipient CD4⁺ cells increased the number of donor cells needed to induce GVHD, depletion of recipient CD8⁺ and natural killer cells resulted in fewer donor cells being needed to induce a GVHD response . These studies suggest a central role for functioning recipient CD8 and natural killer(NK) cells in the downregulation of TA-GVHD development in recipients who receive blood from a haploidentical donor.

INTRODUCTION

Graft-versus-host disease(GVHD) can occur following bone marrow transplantation(BMT), solid organ transplantation or transfusion of leukocyte containing blood.¹⁻³ The GVHD that follows BMT is clinically similar to the GVHD that is associated with blood transfusion(TA-GVHD) except that the TA-GVHD is almost invariably fatal within 30 days, while BMT-GVHD can often be controlled. Possible factors that may explain the greater intensity of the TA-GVHD response include the immune status of the recipient, the number of lymphoid cells transfused and the viability of the lymphocytes which depends on the length of time that the blood had been stored. Particular emphasis has been placed on the seeming lack of recipient immune response in the development of TA-GVHD.⁴ All of the early reports of TA-GVHD were in patients who expressed impaired immunity as a result of inherited immunodeficiency, or as a result of receiving immunosuppressive or chemotherapeutic drugs. However recent studies have found that TA-GVHD could also occur in patients who were presumed to be immunocompetent. In many of the cases where both donor and recipient were HLA typed it was found that the HLA heterozygous recipient had received blood from a donor that was homozygous for one of the recipient's HLA haplotypes.⁵⁻⁸ In this situation, the recipient lymphocytes would perceive the donor cells as self and thus would not respond to donor cells while the donor cells would recognize the recipient cells as foreign and generate a response. Thus it would be predicted that the only immune response possible in this situation would be a donor anti-recipient response. These findings would indicate that a lack of recipient anti-donor response is a critical element in the development of TAGVHD and may contribute to the severity of TA-GVHD. However, if this is true why have there been no reported TA-GVHD cases in severely immunodeficient AIDS patients? Moreover, theoretical calculations of the frequency of a HLA heterozygous recipient receiving blood from a homozygous donor would indicate that the incidence of

TA-GVHD in immunocompetent individuals is much lower than its predicted frequency implying that a protective host response to donor lymphocytes must exist.^{8, 9}

Determination of an explanation for these observations is difficult to study in human patients because of 1) the lack of routine HLA typing for donor and recipients, 2) the variables introduced by the underlying conditions which require a blood transfusion and 3) the limited ability to manipulate the immune system. A mouse model of GVHD enables the investigator to overcome many of these shortcomings with the expectation that the findings would be applicable to the human patients because of the many similarities of the murine and human immune system. A mouse model of GVHD that mimics the immune conditions in TA-GVHD has been extensively studied in this laboratory.¹⁰⁻¹⁴ GVHD is induced by the intravenous injection of homozygous parental spleen cells into unirradiated immunocompetent F₁ hybrid recipients. This is analogous to the HLA combination in humans which appears to be conducive to the development of TAGVHD. The resulting murine GVHD is similar to TA-GVHD because it induces severe hypoplasia of the lympho-hemopoietic system leading to severe pancytopenia.¹⁵ This murine model was used to assess the role that the recipient immune system plays in the regulating GVHD responses in this donor/recipient combination and the results indicated that functional recipient CD8⁺ and NK cells play an important role in preventing GVHD in this donor/recipient combination.

MATERIALS AND METHODS

Mice. C57BL/6, CBA and B6D2F₁ mice were obtained from Jackson Laboratory, Bar Harbor, Maine. All protocols using mice have been approved by the Rhode Island Hospital Animal Welfare Committee.

Antibodies. The antibodies used in these experiments include 2.43(rat IgG2b, anti-Ly 2.2, ATCC)¹⁶, GK1.5(rat IgG2b, anti-L3T4, ATCC)¹⁷ and YTH 89.1.8(rat IgG2b, anti-human glycophorin, obtained from Dr. Herman Waldmann).¹⁸ Commercially obtained antibodies included rabbit anti-asialo GM1(986-1001, Wako, Richmond, VA) which is used for in vivo depletion of NK cells.^{19, 20}

In vivo administration of lymphoid cells and other reagents. Lymphoid cells were injected intravenously in the lateral tail vein of recipient mice by injecting the indicated number of donor cells in 0.2 ml PBS. Spleen cells were obtained from the recipient mice on day 14 following injection of donor cells for functional testing unless indicated otherwise. Some of the recipients had also been injected i.p. with 1 ml of monoclonal antibody culture supernatant 5 days or 100 ul of anti-asialo GM1(diluted 1:5 with PBS) 1 day prior to use as recipients. Some of the recipients were injected i.p. with 200 ug of poly I:C(P-5764, Sigma, St. Louis, MO) in PBS 1 day prior to injection of donor cells. Poly I:C induces the production of interferon which activates NK cell activity.²¹

Functional assays. Spleen cells obtained from recipient B6D2F₁(H-2^{b/d}) mice previously injected with allogeneic C57BL/6(H-2^b) cells were tested for their functional capacity as previously described.¹¹ The ability of the spleen cells to lyse 10⁴ ⁵¹Cr-labelled P815(H-2^d) target cells at the effector to target ratio of 150:1, 75:1, 37.5:1, and 19:1 was measured in a 4 hour lysis assay. Cytokine production by the spleen cells from

GVHD mice was measured by culturing 1.25×10^6 cells/ml of MLC medium alone or by including Con A(5ug/ml, C-2010, Sigma) or LPS(10 ug/ml, 3923-25, Difco, Detroit, MI) to stimulate cytokine production. Con A stimulates the production of interferon- γ (IFN- γ) and LPS stimulates the production of tumor necrosis factor- α (TNF- α).²² The supernatants were collected and stored frozen at -20°C until levels of IFN- γ and TNF- α were measured using ELISA assays(80-2802-00 and 1557-00, Genzyme, Cambridge, MA).

RESULTS

Injection of C57BL/6 spleen cells into B6D2F₁ recipients results in an acute form of GVHD. One of the hallmarks of acute GVHD is the presence of CD8⁺ cytolytic T lymphocytes of donor origin which specifically lyse target cells expressing recipient MHC antigens.¹¹ In these experiments the effect of manipulating the recipient was evaluated by determining the number of C57BL/6 splenic donor cells required to generate detectable donor anti-recipient CTL as a measure of acute GVHD. The first set of experiments compared the effects of depleting recipient CD4⁺ or CD8⁺ cells on the development of GVHD. The results indicate that depletion of recipient CD8⁺ cells permitted 4 fold fewer donor cells to generate an acute GVHD response(Figure 1). In contrast, depletion of CD4⁺ cells resulted in additional donor cells being required to induce an acute GVHD response. NK cells have also been implicated in removal of allogeneic cells.²³ Depletion of NK cells was accomplished by administration of anti-asialo GM1 antisera and was found to result in a 2 fold reduction of the number of donor cells required to induce GVHD(Figure 2). Consistent with this finding, the presence of increased NK cell activity as a result of poly I:C injection required at least 2 fold more donor cells to induce a GVHD response(Figure 3).

One possible explanation for the minimum number of donor cells that are required to induce an acute GVHD response is that a certain number of donor cells are lost as a result of nonspecific trapping. If this were the case addition of carrier cells syngeneic with the recipient should permit fewer number of C57BL/6 donor cells to induce a GVHD response. Addition of 50×10^6 B6D2F₁ cells to varying numbers ($10 - 100 \times 10^6$) of C57BL/6 donor cells did not effect the GVHD responses of the C57BL/6 cells(data not shown). Induction of TA-GVHD is often associated with the receipt of a blood transfusion from a donor homozygous for one the the recipient's MHC haplotypes. One

possibility is that the appearance of TA-GVHD in this situation could be facilitated by the immune responses that result from a blood transfusion received simultaneously from a donor that is allogeneic to both the recipient and the homozygous donor. This possibility was assessed by adding from $10 - 75 \times 10^6$ allogeneic CBA/J(H-2^k) spleen cells to varying numbers of C57BL/6(H-2^b) donor spleen cells and measuring the GVHD response that occurred when these cells were injected into B6D2F₁ (H-2^{b/d}) recipients. The results of seven experiments indicated only minimal and inconsistent changes were detected in the ability of the C57BL/6 cells to induce a GVHD response in this model system as a result of coinjecting allogeneic donor cells(data not shown).

Because production of cytokines such as IFN- γ and TNF have been implicated in the pathogenesis of GVHD²⁴, the production of TNF and IFN- γ was compared to the development of donor anti-recipient CTL following the injection of varying numbers of donor lymphoid cells into unirradiated B6D2F₁ recipients. TNF- α production and CTL generation were found to be inversely correlated in that there was no TNF- α production in those combinations which generated donor anti-recipient CTL(Figure 4). In contrast, increased IFN- γ production correlated with increased CTL activity and could still be detected at a donor cell dose which did not induce donor anti-recipient CTL (25×10^6 cells, Figure 4).

DISCUSSION

TA-GVHD and the acute form of BMT-GVHD manifest similar symptoms except for the more severe pancytopenia that is found in TA-GVHD. Why is TA-GVHD so much more severe with death occurring in almost all cases within 30 days? A possible explanation is that the conditions that permit TA-GVHD generate a much stronger donor anti-recipient response. This could be due in part to a lack of recipient anti-donor responses. Although BMT recipients undergo intensive conditioning prior to receiving the bone marrow inoculum, there are recipient anti-donor responses which can still function. This has been shown by the finding of an increased incidence of graft rejection following transplant of T cell-depleted bone marrow cells.²⁵ In this regard it is interesting that in most of the cases of TA-GVHD that have been analyzed so far the the HLA heterozygous recipient had received blood from a donor that is homozygous for one of the recipient's HLA haplotypes. In this combination a lack of a specific recipient anti-donor response would be predicted. This is because T lymphocytes which undergo a negative selection step have been selected not to respond to self MHC molecules.²⁶ In this combination T cells would see leukocytes from the donor as self while the donor cells recognize the allogeneic HLA antigens expressed on recipient cells as foreign. Although this combination would be predicted to limit the response to a donor anti-recipient response it is clear that the frequency of TA-GVHD is much lower than the calculated frequency of which a HLA heterozygous recipient receives blood from a donor homozygous for one the recipient's HLA haplotypes.⁹

What is the explanation for the discrepancy between the frequency of the donor/recipient combination and the incidence of TA-GVHD? One possible explanation is that although the recipient lymphocytes are unable to mediate specific immune responses in this donor/recipient combination they may generate nonspecific responses which are able to regulate the donor cells in this situation. In this study we have shown that recipient CD8⁺

cells and NK cells are capable preventing GVHD responses of donor cells. How can these cells nonspecifically mediate this effect? Activation of recipient NK cells has been shown to promote the elimination of injected allogeneic cells.²³ Cytokines such as IFN- γ which are produced as a result of the donor anti-recipient response could activate recipient NK cells and enhance their ability to eliminate the donor cells. Nonspecific functions mediated by CD8⁺ cells include veto cell activity. Veto cells are cells which inactivate CTL precursor cells which recognize and bind to the veto cell and have been implicated in the development of transplantation tolerance.²⁷ The specificity is supplied by the CTL precursor cells not the veto cells. In the same murine GVHD model used for these experiments recipient F₁ CD8⁺ cells have been shown to inhibit the donor cytolytic response by acting as veto cells.^{13, 14} These B6D2F₁ veto cells were found to be radiosensitive, inhibited by anti-CD8 and potentiated by incubation with IL-2. Similarly, CD8⁺ cells which inhibited donor anti-host responses could be identified in post transfusion responses.²⁸ These findings also provide an explanation for the lack of reported TA-GVHD in AIDS patients following transfusion. Although these patients are immunosuppressed because of a lack of CD4⁺ cell function, CD8⁺ cells are still functional in these patients until the advanced stages of the disease.²⁹

These results would suggest that procedures or conditions which result in the lack of recipient CD8 and NK cell function would be conducive to the development of TA-GVHD. For example anesthesia and surgery has been shown to be associated with a depression in cell-mediated immunity.³⁰ This is manifested by a decrease in T and NK cell number and by depressed in vitro responses to mitogens and antigens and by depressed DTH responses in vivo. The magnitude of the depression in immune responses is increased as the extent of the surgery increases. The development of TA-GVHD has often been found to be associated with the recipient receiving blood when undergoing

major surgery correlating the loss of recipient immune function with increased incidence of TAGVHD.^{5, 6}

It has been proposed that the symptoms associated with GVHD are the result of dysregulation of the production of inflammatory cytokines including IL-1, IL-2, and TNF- α .²⁴ This hypothesis has been supported by the finding that administration of TNF- α generates GVHD lesions and inhibition of TNF reduces the severity of GVHD.²⁴ Inhibition of IL-1 using IL-1 receptor antagonist also blocked the development of GVHD symptoms.^{31, 32} These studies have been done in murine models of bone marrow transplantation using irradiated recipients. Analysis of the production of cytokine mRNA 14 days after the injection of C57BL/6 spleen cells into unirradiated B6D2F₁ recipients detected increased mRNA levels for IL-1 α , IL-10, IFN- γ , and MIP-1 α and decreased mRNA levels for TNF- β .³³ Unchanged mRNA levels for TNF- α were detected. Thus our findings of increased IFN- γ correlated with increased levels of mRNA. However despite no change in mRNA levels there was decreased production of TNF- α . Additional studies using mice which are selectively unable to produce cytokines such as IFN- γ or TNF- α or mediate cytolytic activity will help distinguish whether cytokine production or cytolytic activity is important for the development of GVHD.

These findings would suggest that any recipient with impaired CD8 and/or NK cells or who will be undergoing a procedure which inhibits the function of CD8 and/or NK cells would be at increased risk for developing TAGVHD. This would be especially true if they also received a blood transfusion from an individual that is homozygous for one of their HLA haplotypes and if the blood contains large numbers of viable lymphocytes. Since the threshold number of lymphocytes in blood products below which TA-GVHD would not occur is unknown, irradiation of transfused blood in the clinical settings where

impaired recipient NK or CD8⁺ cell function has been identified would be expected to reduce the risk of developing TA-GVHD.

ACKNOWLEDGEMENTS.

We would like to thank Joann Ferland, Jacqui Poore and Gilbert DiLeone for their excellent technical assistance.

REFERENCES

1. Blumberg N, Heal JM: Immunology of blood transfusion. *Current Opinion in Hematology* 330, 1993
2. Anderson KC, Weinstein HJ: Transfusion-associated graft-versus-host disease. *N Engl J Med* 323:315, 1990
3. Greenbaum BH: Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products. *J Clin Onc* 9:1889, 1991
4. Brubaker DB: Immunopathogenic mechanisms of posttransfusion graft-vs-host disease. *Proc Soc Exp Biol Med* 202:122, 1993
5. Thaler M, Shamiss S, Orgad S, Huszar M, Nussinovitch N, Meisel S, Gazit E, Lavee J, Smolinsky A: The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open heart surgery. *N Engl J Med* 321:25, 1989
6. Juji T, Takahashi Y, Shibata H, Ide H, Sakakibara T, Ino T, Mori S: Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. *N Engl J Med* 321:56, 1989
7. Shivadasani RA, Haluska FG, Dock NL, Dover JS, Kineke EJ, Anderson KC: Brief Report: Graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. *N Engl J Med* 328:766, 1993
8. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ: HLA-homozygous donors and transfusion-associated graft-versus-host disease. *N Engl J Med* 322:1005, 1990
9. Ohto H, Yasuda H, Noguchi M, Abe R: Risk of transfusion-associated graft-versus-host disease as a result of direct donations from relatives. *Transfusion* 32:691, 1992
10. Fast LD: DBA/2J and DBA/2Ha lymphocytes differ in their ability to induce graft-versus-host disease. *J Immunol* 143:2389, 1989

11. Fast LD: Identification of a single non-H-2 gene regulating graft-versus-host disease response. *J Immunol* 144:4177, 1990
12. Fast LD, Kouttab NM, Badamchioan M, Goldstein AL: Thymic hormone modulation of age-induced changes in the induction of graft-versus-host disease by DBA/2J lymphocytes. *Cellular Immunology* 131:232, 1990
13. Fast LD: In vitro characterization of a murine recipient anti-donor effector cell responsible for the development of chronic graft-versus-host disease. *J Immunol* 147:1731, 1991
14. Fast LD: Generation and characterization of IL-2 activated veto cells. *J Immunol* 149:1510, 1992
15. Gleichman E, Pals ST, Rolink AG, Radaszkiewicz T, Gleichman H: Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. *Immunol. Today* 5:324, 1984
16. Sarmiento M, Glasebrook AL, Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytotoxicity in the absence of complement. *J Immunol* 125:2665, 1980
17. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintáns J, Loken MR, Pierres M, Fitch FW: Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. *J Immunol* 131:2445, 1983
18. Galfre G, Milstein C, Wright B: Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. *Nature* 277:131, 1979
19. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N: In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. *J Immunol* 127:34, 1981

20. Kasai M, Yoneda T, Habu S, Maruyama Y, Okumura K, Tokunaga T: In vivo effect of anti-asialo GM1 antibody on natural killer activity. *Nature* 291:334, 1981
21. Gidlund M, Orn A, Wigzell H, Senik A, Gresser I: Enhanced NK cell activity in mice injected with interferon and interferon inducers. *Nature* 273:759, 1978
22. Smith SR, Terminelli C, Kenworthy-Bott L, Phillips DL: A study of cytokine production in acute graft-vs-host disease. *Cellular Immunol* 134:336, 1991
23. Sheng-Tanner X, Miller RG: Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation. *J Exp Med* 176:407, 1992
24. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. *Blood* 80:2964, 1992
25. Quinones RR. Hematopoietic engraftment and graft failure after bone marrow transplantation *Am J Ped Hema-Onc* 15:3, 1993
26. Nossal GJV: Negative selection of lymphocytes. *Cell* 76:229, 1994
27. Thomas JM, Verbanac KM, Carver FM, Kasten-Jolly J, Haisch CE, Gross U, Smith JP: Veto cells in transplantation tolerance. *Clinical Transpl.* 8:195, 1994
28. Van der Mast BJ, Hornstra M, Ruigrok MB, Claas FHJ, van Rood JJ, Lagaaij EL: Transfusion-associated graft-versus-host disease in immunocompetent patients: a self-protective mechanism. *Lancet* 343:753, 1994
29. Landay AL, Mackewicz CE, Levy JA: An activated CD8⁺ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. *Clin. Immunol. Immunopathol.* 69:106, 1993
30. Salo M: Effects of anaesthesia and surgery on the immune response. *Acta Anaesthesiol Scand* 36:201, 1992
31. Ferrara JLM, Abhyankar S, Gilliland DG: Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. *Transplantation Proceedings* 25:1216, 1993

32. McCarthy PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, Burakoff SJ, Ferrara JLM: Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. *Blood* 78:1915, 1991
33. Allen RD, Staley TA, Sidman CL: Differential cytokine expression in acute and chronic murine graft-versus-host disease. *Eur J Immunol* 23:333, 1993

Figure 1. The effect of T cell subset depletion on the number of donor splenocytes required to induce a GVHD response. B6D2F₁ recipient mice were injected with anti-CD4(GK 1.5, ) , anti-CD8(2.43, ) , or control antibody(YTH 89.1.8, ) and then were injected with the indicated number of C57BL/6 donor spleen cells. The presence of donor anti-recipient CTL was assessed by testing the ability of spleen cells obtained from the recipient mice 14 days after injection to lyse P815 target cells(150:1 effector to target ratio). This data is from a representative experiment of 3 such experiments.

Figure 2. The effect of depleting NK cells on the number of donor splenocytes required to induce a GVHD response. B6D2F₁ mice were injected with rabbit anti-asialo GM1 () or normal rabbit serum() and then injected with the indicated number of C57BL/6 spleen cells. The presence of donor anti-recipient CTL was assessed by testing the ability of spleen cells obtained from the recipient mice 14 days later.to lyse P815 target cells(150:1 effector to target ratio). This is a representative experiment of 3 such experiments.

Figure 3. The effect of injecting poly I:C on the number of donor splenocytes required to induce a GVHD response. B6D2F₁ mice were injected with poly I:C() or PBS() and then injected with indicated number of C57BL/6 donor spleen cells. The presence of donor anti-recipient CTL was assessed by testing the ability of spleen cells obtained from the recipient mice 14 days later.to lyse P815 target cells(150:1 effector to target ratio). This is a representative experiment of 3 such experiments.

Figure 4. The effect of donor cell dose on donor anti-recipient CTL responses and the production of TNF- α and IFN- γ . B6D2F₁ mice were injected with the indicated dose of C57BL/6 spleen cells. Fourteen days later the spleen cells were obtained from these recipient mice and the presence of donor anti-recipient CTL was assessed by testing the ability of spleen cells obtained from the recipient mice 14 days later to lyse P815 target cells (150:1 effector to target ratio, C), for the cells ability to produce TNF- α (A) when cultured overnight in medium (■) or with LPS (▨), or for IFN- γ production (B) in overnight culture with medium (■) or with Con A (▨). This is a representative experiment of 3 such experiments.







